View Future GrowthCopley Acquisition 과거 순이익 실적과거 기준 점검 2/6Copley Acquisition의 연간 평균 수익은 271.5%였으며, Capital Markets 산업의 수익은 연간 7.2% 증가했습니다.핵심 정보271.50%순이익 성장률n/a주당순이익(EPS) 성장률Capital Markets 산업 성장률10.26%매출 성장률n/a자기자본이익률n/a순이익률n/a최근 순이익 업데이트30 Jun 2026최근 과거 실적 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Aug 19Copley Acquisition Corp announced delayed 10-Q filingOn 08/17/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공고 • Jun 12Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction.Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction on June 10, 2026. The aggregate consideration to be paid to holders of Ignite’s membership interests as of the Effective Time (collectively, the “ Sellers ”) pursuant to the Company Merger shall consist of a number of newly issued shares of Pubco Common Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000) divided by Ten U.S. Dollars ($10.00) (the “ Merger Consideration ”). The transaction implies an enterprise value of $150 million for Ignite Proteomics. Upon completion, Ignite will merge with a subsidiary of a newly formed public company, Ignite Proteomics Holdings, Inc. ("Pubco"), and will become a wholly-owned subsidiary of Pubco. Copley Acquisition Corp. will also merge into a subsidiary of Pubco, with Pubco becoming the new publicly traded entity. The Parties shall take all necessary action, including causing the directors of the Pubco to resign, so that effective as of the Closing, Pubco’s board of directors (the “ Post-Closing Pubco Board ”) will consist of seven (7) individuals. Immediately after the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Pubco Board those persons designated by the Company prior to the Closing (the “ Company Directors ”), at least four (4) of whom shall be required to qualify as an independent director under NYSE rules and one (1) of whom shall be the chief executive officer of the Company. The obligations of the parties to consummate the Transactions are subject to various conditions, including the following mutual conditions of the parties, unless waived: (i) the approval of the Business Combination Agreement and the Transactions and related matters by the requisite vote of each of Copley’s shareholders and Ignite’s members; (ii) the expiration or termination of any waiting period applicable to the consummation of the Business Combination Agreement under any antitrust laws; (iii) obtaining material regulatory approvals; (iv) obtaining or making the Consents required to be obtained from or made with third Persons; (v) no law or order preventing or prohibiting the Transactions; (vi) appointment of the Post-Closing Pubco Board consistent with the requirements of the Business Combination Agreement; (vii) the effectiveness of the Registration Statement; (viii) the Conversion shall have been consummated; (ix) Pubco shall have amended and restated its certificate of incorporation in a form satisfactory to Copley and Ignite; (x) shares of Pubco Common Stock and Pubco Public Warrants shall have been approved for listing on the NYSE upon the Closing. The transaction has been approved by the board of directors of Copley Acquisition and Ignite Proteomics. Clear Street LLC is acting as the financial advisor to Copley. Mike Blankenship of Winston Taylor LLP is acting as legal counsel to Copley. Ladenburg Thalmann & Co. Inc. is acting as the financial advisor to Ignite Proteomics. Louis Lombardo of Meister Seelig & Schuster PLLC is acting as legal counsel to Ignite Proteomics.공고 • May 17Copley Acquisition Corp announced delayed 10-Q filingOn 05/15/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Negative equity (-US$44k). Revenue is less than US$1m.매출 및 비용 세부 내역Copley Acquisition가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이NYSE:COPL 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비30 Jun 26061031 Mar 26051031 Dec 250400양질의 수익: COPL는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 지난 1년 동안 COPL의 이익률이 개선되었는지 판단하기에 데이터가 부족합니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: COPL은 상장된 지 3년이 되지 않아 지난 5년간 전년 대비 수익 증가율이 긍정적인지 확인할 수 없습니다.성장 가속화: COPL은 상장된 지 3년이 되지 않아 지난 해 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: COPL의 지난 1년 수익 증가율(271.5%)은 Capital Markets 업계의 34.3%를 상회했습니다.자기자본이익률높은 ROE: COPL의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YDiversified-financials 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/08/23 21:12종가2026/08/21 00:00수익2026/06/30연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Copley Acquisition Corp는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공고 • Aug 19Copley Acquisition Corp announced delayed 10-Q filingOn 08/17/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공고 • Jun 12Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction.Ignite Proteomics LLC entered into a definitive business combination agreement to acquire Copley Acquisition Corp (NYSE:COPL) from Copley Acquisition Sponsors, LLC and others for approximately $160 million in a reverse merger transaction on June 10, 2026. The aggregate consideration to be paid to holders of Ignite’s membership interests as of the Effective Time (collectively, the “ Sellers ”) pursuant to the Company Merger shall consist of a number of newly issued shares of Pubco Common Stock equal to One Hundred and Fifty Million U.S. Dollars ($150,000,000) divided by Ten U.S. Dollars ($10.00) (the “ Merger Consideration ”). The transaction implies an enterprise value of $150 million for Ignite Proteomics. Upon completion, Ignite will merge with a subsidiary of a newly formed public company, Ignite Proteomics Holdings, Inc. ("Pubco"), and will become a wholly-owned subsidiary of Pubco. Copley Acquisition Corp. will also merge into a subsidiary of Pubco, with Pubco becoming the new publicly traded entity. The Parties shall take all necessary action, including causing the directors of the Pubco to resign, so that effective as of the Closing, Pubco’s board of directors (the “ Post-Closing Pubco Board ”) will consist of seven (7) individuals. Immediately after the Closing, the Parties shall take all necessary action to designate and appoint to the Post-Closing Pubco Board those persons designated by the Company prior to the Closing (the “ Company Directors ”), at least four (4) of whom shall be required to qualify as an independent director under NYSE rules and one (1) of whom shall be the chief executive officer of the Company. The obligations of the parties to consummate the Transactions are subject to various conditions, including the following mutual conditions of the parties, unless waived: (i) the approval of the Business Combination Agreement and the Transactions and related matters by the requisite vote of each of Copley’s shareholders and Ignite’s members; (ii) the expiration or termination of any waiting period applicable to the consummation of the Business Combination Agreement under any antitrust laws; (iii) obtaining material regulatory approvals; (iv) obtaining or making the Consents required to be obtained from or made with third Persons; (v) no law or order preventing or prohibiting the Transactions; (vi) appointment of the Post-Closing Pubco Board consistent with the requirements of the Business Combination Agreement; (vii) the effectiveness of the Registration Statement; (viii) the Conversion shall have been consummated; (ix) Pubco shall have amended and restated its certificate of incorporation in a form satisfactory to Copley and Ignite; (x) shares of Pubco Common Stock and Pubco Public Warrants shall have been approved for listing on the NYSE upon the Closing. The transaction has been approved by the board of directors of Copley Acquisition and Ignite Proteomics. Clear Street LLC is acting as the financial advisor to Copley. Mike Blankenship of Winston Taylor LLP is acting as legal counsel to Copley. Ladenburg Thalmann & Co. Inc. is acting as the financial advisor to Ignite Proteomics. Louis Lombardo of Meister Seelig & Schuster PLLC is acting as legal counsel to Ignite Proteomics.
공고 • May 17Copley Acquisition Corp announced delayed 10-Q filingOn 05/15/2026, Copley Acquisition Corp announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
New Risk • Apr 02New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended December 2024. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2024 fiscal period end). Negative equity (-US$44k). Revenue is less than US$1m.